• OPEN AN ACCOUNT
Indian Indices
Nifty
15,835.35 83.30
(0.53%)
Sensex
53,234.77 326.84
( 0.62%)
Bank Nifty
33,940.90 401.45
( 1.20%)
Nifty IT
27,890.65 -173.60
( -0.62%)
Global Indices
Nasdaq
11,127.85 99.11
(0.90%)
Dow Jones
31,097.26 321.83
(1.05%)
Hang Seng
21,830.35 -29.44
(-0.13%)
Nikkei 225
26,153.81 218.19
(0.84%)
Forex
USD-INR
78.81 0.07
(0.10%)
EUR-INR
82.25 -0.34
(-0.41%)
GBP-INR
95.25 -0.48
(-0.51%)
JPY-INR
0.58 0.01
(0.90%)

EQUITY - MARKET SCREENER

Rajnish Wellness Ltd
Industry :  Trading
BSE Code
ISIN Demat
Book Value()
541601
INE685Z01017
32.2128339
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
N.A
0
589.04
EPS(TTM)
Face Value()
Div & Yield %
0.15
10
0
 

Cipla Ltd
Cipla receives USFDA final approval for Lanreotide Injection
Dec 20,2021
Cipla announced that it has received final approval for its Lanreotide Injection, from the United States Food and Drug Administration (US FDA). The FDA approval was based on a New Drug Application (NDA) submitted under the 505(b)(2) filing pathway.

Lanreotide Injection is supplied in 60 mg/0.2 mL, 90 mg/0.3 mL, and 120 mg/0.5 mL singledose pre-filled syringes. It is indicated for the treatment of patients with Acromegaly and Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs).

The active ingredient, route of administration and strengths are the same as SOMATULINE DEPOT®, from Ipsen Biopharmaceuticals Inc. According to IQVIA, SOMATULINE DEPOT® had US sales of approximately $867M for the 12-month period ending October 2021.